Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Agilent (A), Agilon Health (AGL) and Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Feb 27, 6:29AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Agilent (A – Research Report), Agilon Health (AGL – Research Report) and Sarepta Therapeutics (SRPT – Research Report).

Claim 50% Off TipRanks Premium

Agilent (A)

J.P. Morgan analyst Casey Woodring maintained a Buy rating on Agilent today and set a price target of $180.00. The company’s shares closed last Wednesday at $124.72.

According to TipRanks.com, Woodring is a 1-star analyst with an average return of -4.6% and a 40.2% success rate. Woodring covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Agilent has an analyst consensus of Strong Buy, with a price target consensus of $168.20, representing a 34.0% upside. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $157.00 price target.

See today’s best-performing stocks on TipRanks >>

Agilon Health (AGL)

In a report released today, Matthew Shea from Needham reiterated a Hold rating on Agilon Health. The company’s shares closed last Wednesday at $0.50.

According to TipRanks.com, Shea has 0 stars on 0-5 stars ranking scale with an average return of -32.7% and a 14.3% success rate. Shea covers the Healthcare sector, focusing on stocks such as Oncology Institute, Astrana Health, and Evolent Health. ;'>

Agilon Health has an analyst consensus of Hold, with a price target consensus of $0.88, representing a 120.0% upside. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

Sarepta Therapeutics (SRPT)

J.P. Morgan analyst Anupam Rama reiterated a Hold rating on Sarepta Therapeutics yesterday. The company’s shares closed last Wednesday at $18.97.

According to TipRanks.com, Rama is a 5-star analyst with an average return of 19.9% and a 52.5% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $22.27, which is a 18.1% upside from current levels. In a report released today, Morgan Stanley also maintained a Hold rating on the stock with a $20.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).